Abstract
Mental and cognitive impairments are common non-motor symptoms of Parkinson's disease (PD), which affect more than half of patients at various stages of the disease. These symptoms significantly reduce the quality of life of patients and their relatives. The article reflects the features of the pathogenesis of mental and cognitive impairments in PD, as well as the role of the dopamine receptor agonist piribedil in their correction. Piribedil, having a good safety and tolerability profile, and also, presumably, having a positive effect on such non-motor symptoms of PD as increased daytime sleepiness, depression, apathy, anhedonia and cognitive functions, can significantly improve the quality of life of patients and their adherence to therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
